Key findings from detailed records
A specific Curcuma longa extract reduced knee-pain scores versus placebo over 12 weeks in 70 people with knee osteoarthritis; the difference was 9.1 mm on the pain scale. MRI measures did not demonstrate structural joint improvement. Extract composition matters: this was not a trial of 1,000 mg pure curcumin.
KNOWLEDGE RECORD
- Category
- Skin and connective tissue
- Last Reviewed
Names and related search termsCurcumin / Curcumin / Curcuma longa / Turmeric extract
Study type: human intervention study.
OUTCOME-SPECIFIC EVIDENCE
Scientific Evidence Profile
Assessment pending
An outcome-specific assessment has not yet been completed. This is not a finding that the ingredient is ineffective. The study records below remain available.
This profile concerns the stated outcome and population, not the ingredient as a whole. It is not a probability of benefit, a safety rating, a product efficacy rating or an indication of product adoption.
How we assess evidenceIngredient Profile
- What is it?
- Curcumin is a natural pigment from turmeric. It has a beta-diketone structure; turmeric as a food contains more than this one compound. [1]
Sources for this profile
Compound properties and formulation properties are different. These sources do not establish the efficacy of a finished supplement.
- PubChem — Curcumin (CID 969516) Chemical identity reference. Maintained by NCBI, U.S. National Library of Medicine. Database record; not a clinical trial.
Profile sources checked:
Read the evidence in context
- Evidence: what was measured in the stated population or experimental model.
- Inference: an interpretation connecting findings; its applicability depends on the study conditions.
- Hypothesis: a proposed explanation or effect that remains to be tested.
Why It Matters #
Is pain relief the same as structural change in a joint? Check the detailed records for study conditions and use the literature map to compare other populations and outcomes.
What Was Studied #
70 people with symptomatic knee osteoarthritis and effusion–synovitis Randomized, double-blind, placebo-controlled trial. Outcomes: Knee pain VAS and MRI effusion–synovitis volume[1]
What Was Found #
Between-group pain difference: −9.1 mm (95% CI −17.8 to −0.4). No significant improvement in MRI volume or cartilage composition.[1]
What the Evidence Means #
A small, short-term study of a specific extract. The practical meaning of the statistically significant pain score difference also needs consideration.[1]
Comparing similar populations, formulations, durations and outcomes helps identify where findings agree and where they differ.
What We Can Learn #
This specific turmeric extract improved knee-pain scores over 12 weeks. Symptom relief and structural joint changes are different outcomes: MRI findings did not demonstrate joint repair.
What Remains Unknown #
Further questions include reproducibility across populations and formulations, and the long-term balance of benefits and harms. Use the literature map as a starting point for these questions.
LITERATURE MAP / 10 PAPERS
Compare papers by conditions and findings.
A literature map covering different populations, outcomes and formulations. Read alongside detailed records to avoid treating one trial as the conclusion for an entire ingredient.
Selected: 2026-09-21. Bibliographic information checked against Europe PMC / PubMed. Editorial selection considered major papers and a range of populations and questions. This is not a systematic search covering all recent research.
10 RECORDS
A dash marks fields outside the bibliographic record. Use detailed records to compare findings and design records to connect mechanisms.
No papers match. Change the search conditions.
The literature map is an index of research questions and references. Individual assessment of results, doses, funding and COI is limited to the detailed study records. Related reports from the same trial may be included; paper counts are not counts of independent trials.
Explore the research Study Records
Listed doses describe study conditions, not recommended intake.
CurKOA conference report — formulation
Effectiveness of Curcuma longa Extract for the Treatment of Symptoms and Effusion-Synovitis of Knee Osteoarthritis : A Randomized Trial.
PubMed 32926799DOI: 10.7326/m20-0990
- Authors
- Wang Z, Jones G, Winzenberg T, Cai G, Laslett LL, Aitken D, Hopper I, Singh A, Jones R, Fripp J, Ding C, Antony B.
- Journal
- Annals of internal medicine
- Publication year
- 2020
- Study design
- Randomized, double-blind, placebo-controlled trial
- Participants
- 70 people with symptomatic knee osteoarthritis and effusion–synovitis
- Dose and intervention
- The same trial’s 2020 conference report specifies 2 × 500 mg/day of a Curcuma longa extract: 80% aqueous extract standardized to turmerosaccharides and 20% curcuminoids. This is extract mass, not 1,000 mg of pure curcumin.
- Duration
- 12 weeks
- Outcomes and their role in the study
- Knee pain VAS and MRI effusion–synovitis volume
- Findings
- Between-group pain difference: −9.1 mm (95% CI −17.8 to −0.4). No significant improvement in MRI volume or cartilage composition.
- Limitations
- A small, short-term study of a specific extract. The practical meaning of the statistically significant pain score difference also needs consideration.
- Funding
- University of Tasmania and Natural Remedies Private Limited, as reported in the final trial abstract.
- Conflict of Interest
- The authors declared no conflicts in the CurKOA conference report (2020). This declaration is from that report; the final journal disclosure forms have not been inspected. Industry funding is reported separately above.
- Scope of source review
- Final trial abstract checked for population, outcomes and funding; the same trial’s 2020 conference report supplies formulation and COI information. Sources are distinguished rather than treated as independent trials.
Cite this page
LÍFSVARÐA. Curcumin: Is pain relief the same as structural change in a joint? Version 1.1 / Updated 2026-10-24
https://lifsvarda.com/knowledge/curcumin/Edited by LÍFSVARÐA (product brand).Editorial policy
Safety and interactions
Curcumin formulations differ in absorption and safety. Liver injury has been reported with some formulations that increase bioavailability. Stop use and seek medical advice if jaundice, dark urine or persistent nausea develops. Findings from a particular extract do not establish the safety of every curcumin formulation.
Safety section reviewed: 2026-10-24.
Sources and updates
- Wang Z, Jones G, Winzenberg T, Cai G, Laslett LL, Aitken D, Hopper I, Singh A, Jones R, Fripp J, Ding C, Antony B. (2020). Effectiveness of Curcuma longa Extract for the Treatment of Symptoms and Effusion-Synovitis of Knee Osteoarthritis : A Randomized Trial.Final trial abstract checked for population, outcomes and funding; the same trial’s 2020 conference report supplies formulation and COI information. Sources are distinguished rather than treated as independent trials.
First published: 2026-09-21 / Version 1.1. Updated 2026-09-23: Added a research comparison table and links to design records. Source notes identify the scope of verification when the full paper has not been reviewed. Research summaries and LÍFSVARÐA’s interpretation are distinguished.